(Q50421735)

13 March 2018

title

Position paper: Rationale for the treatment of children with CCSK in the UMBRELLA SIOP-RTSG 2016 protocol. (English)

1 reference

13 March 2018

1 reference

Gema L Ramírez-Villar

Gema L Ramírez-Villar

6

0 references

Beatriz de Camargo

Beatriz de Camargo

14

0 references

Norbert Graf

Norbert Graf

2

0 references

Kathy Pritchard-Jones

17

Kathy Pritchard-Jones

1 reference

PubMed ID

29485128

Marry M van den Heuvel-Eibrink

13 March 2018

18

Marry M van den Heuvel-Eibrink

1 reference

13 March 2018

author name string

Saskia L Gooskens

1

1 reference

13 March 2018

Rhoikos Furtwängler

3

1 reference

13 March 2018

Filippo Spreafico

4

1 reference

13 March 2018

Christophe Bergeron

5

1 reference

13 March 2018

Jan Godzinski

7

1 reference

13 March 2018

Christian Rübe

8

1 reference

13 March 2018

Geert O Janssens

9

1 reference

13 March 2018

Gordan M Vujanic

10

1 reference

13 March 2018

Ivo Leuschner

11

1 reference

13 March 2018

Aurore Coulomb-L'Hermine

12

1 reference

13 March 2018

Anne M Smets

13

1 reference

13 March 2018

Sara Stoneham

15

1 reference

13 March 2018

Harm van Tinteren

16

1 reference

13 March 2018

International Society of Paediatric Oncology–Renal Tumour Study Group (SIOP–RTSG)

19

1 reference

13 March 2018

language of work or name

English

0 references

publication date

27 February 2018

1 reference

13 March 2018

published in

Nature Reviews Urology

1 reference

13 March 2018

Creative Commons Attribution 4.0 International

copyright license

start time

27 February 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/nrurol.2018.14

0 references

cites work

An intersection of pediatrics and geriatrics

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Clear cell sarcomas of the kidney registered on International Society of Pediatric Oncology (SIOP) 93-01 and SIOP 2001 protocols: a report of the SIOP Renal Tumour Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Clear cell sarcoma of the kidney: a review of 351 cases from the National Wilms Tumor Study Group Pathology Center

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Clear cell sarcoma of the kidney: a clinicopathologic study of 21 patients with long-term follow-up evaluation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Clear cell sarcoma of the kidney: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Diffuse and strong cyclin D1 immunoreactivity in clear cell sarcoma of the kidney.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

BCOR Overexpression Is a Highly Sensitive Marker in Round Cell Sarcomas With BCOR Genetic Abnormalities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

TCF21 hypermethylation in genetically quiescent clear cell sarcoma of the kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Whole transcriptome sequencing identifies BCOR internal tandem duplication as a common feature of clear cell sarcoma of the kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Activation of human telomerase reverse transcriptase through gene fusion in clear cell sarcoma of the kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Characterization of the chromosomal translocation t(10;17)(q22;p13) in clear cell sarcoma of kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Consistent in-frame internal tandem duplications of BCOR characterize clear cell sarcoma of the kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

BCOR internal tandem duplication and YWHAE-NUTM2B/E fusion are mutually exclusive events in clear cell sarcoma of the kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Mutually exclusive BCOR internal tandem duplications and YWHAE-NUTM2 fusions in clear cell sarcoma of kidney: not the full story

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

BCOR internal tandem duplications in clear cell sarcoma of the kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

The clinical phenotype of YWHAE-NUTM2B/E positive pediatric clear cell sarcoma of the kidney.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Treatment of children with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Treatment and outcome of patients with relapsed clear cell sarcoma of the kidney: a combined SIOP and AIEOP study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Paediatric renal tumours: perspectives from the SIOP-RTSG.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Effectiveness of preoperative chemotherapy in Wilms' tumor: results of an International Society of Paediatric Oncology (SIOP) clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Sarcomatous Wilms' tumour with clear cells and hyalinization. A study of 38 tumours in children from the SIOP nephroblastoma file.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Results of the Sixth International Society of Pediatric Oncology Wilms' Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms' tumor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Effect of duration of treatment on treatment outcome for patients with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Outcomes of patients with revised stage I clear cell sarcoma of kidney treated in National Wilms Tumor Studies 1-5.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

The treatment of Wilms' tumour: results of the United Kingdom Children's cancer study group (UKCCSG) second Wilms' tumour study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Childhood cancer incidence: is it really going up?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Outcome of pediatric renal tumor treated using the Japan Wilms Tumor Study-1 (JWiTS-1) protocol: a report from the JWiTS group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

National Wilms Tumor Study: an update for pathologists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Malignant tumours of the kidney: imaging strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Clear cell sarcoma of the kidney: CT, sonographic, and pathologic correlation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Ifosfamide, mesna, and nephrotoxicity in children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Chronic ifosfamide nephrotoxicity in children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Effect of childhood cancer treatment on fertility markers in adult male long-term survivors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Acute ovarian failure in the childhood cancer survivor study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Secondary malignant neoplasms of the bladder after cyclophosphamide treatment for childhood acute lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignancies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Cerebrospinal fluid pharmacokinetics of carboplatin in children with brain tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Platinum distribution in malignant glioma following intraoperative intravenous infusion of carboplatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Evaluation of late adverse events in long-term wilms' tumor survivors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors: What do we know and where are we going?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

New Strategies in Stereotactic Radiotherapy for Oligometastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Treatment of recurrent clear cell sarcoma of the kidney with brain metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Salvage treatment of relapsing Wilms' tumour by autologous bone marrow transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Successful double autografts for patients with relapsed clear cell sarcoma of the kidney.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Not too little, not too much-just right! (Better ways to give high dose melphalan).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Late recurrence of clear cell sarcoma of the kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Preoperative versus postoperative radiotherapy, single versus multiple courses of actinomycin D, in the treatment of Wilms' tumor. Preliminary results of a controlled clinical trial conducted by the International Society of Paediatric Oncology (S.I.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Lymph node invasion and prognosis in nephroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

The treatment of Wilms' tumor. Results of the national Wilms' tumor study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

The treatment of Wilms' Tumor: Results of the second national Wilms' Tumor study

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

31 March 2020

12 December 2020

Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Results of the United Kingdom Children's Cancer Study Group first Wilms' Tumor Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Grading quality of evidence and strength of recommendations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.14

Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.

31 March 2020

1 reference

PubMed

12 December 2020

Late effects of treatment for wilms tumor

1 reference

PubMed

12 December 2020

Stage I clear cell sarcoma of the kidney: is it the time for a less intensive adjuvant treatment?

1 reference

PubMed

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2018.14

1 reference

13 March 2018

PubMed ID

29485128

1 reference

13 March 2018